top of page
Pipetting Samples

Therapeutics

FAKnostics has developed a series of hydrocarbon-stapled peptides that block the FAK FAT domain. 


Our peptides have demonstrated enhanced alpha helicity, permeability, binding affinity, proteolytic resistance, and pharmacokinetic properties. 

​

Currently, we have several very promising anti-cancer products in in-vitro, pre-clinical, and pre-IND stages.

In-Vitro

Pre-Clinical

Pre-IND

IND

Melanoma

Liver Fibrosis

Lung Fibrosis

Skin Fibrosis

Pancreatic Cancer

Diagnostics

Multiple companies have developed FAK inhibitors that target the kinase domain of FAK, but most have failed in clinical trials due to innate resistance mechanisms.

​

FAKnostics' inhibitor targets the non-kinase domain, which plays important roles in cancer progression and metastasis.

​

Our FAKnosTest® companion diagnostic is based on our proprietary FAK antibody thoroughly tested on thousands of biopsies.

Cancer Cells IF.png

Proof of Concept

Formulation Optimization

Commercial

FAKnosTest CRC Prognostic

Companion Melanoma

Companion Fibrosis

Companion Pancreatic Cancer

bottom of page